SRPT Stock Price Today (July 2026) — Sarepta Therapeutics, Inc. Analysis & Key Metrics 2026-07-17
Sarepta Therapeutics, Inc. (SRPT) is trading at $17.22, down 0.06% today (as of July 2026). The stock continues to show pressure below major moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $22.00 (27.8% upside).
- Volatility remains elevated (48.35% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (-1.90% YoY) alongside significant competitive pressures.
SRPT Stock Analysis: Key Metrics & Valuation (July 2026)
Concise, actionable data for investors
Sarepta Therapeutics, Inc. - Historical Price & Volume
Market Cap
Enterprise Value: $2.29B
P/E Ratio
Forward P/E: 6.67
Revenue Growth
Year over Year
Analyst Target
+27.8% upside potential
Key Investor Questions About SRPT
What investors need to know before buying
Based on current market data, SRPT presents a neutral technical setup with challenging fundamentals.
- Technicals say: Neutral (RSI 39.90)
- Fundamentals say: Challenging (declining revenue trends)
SRPT's growth trajectory depends on its ability to expand within the Biotechnology sector while managing margin pressures.
- Future growth will depend on performance in core Biotechnology operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for SRPT investors include debt exposure and competitive dynamics in the Biotechnology industry.
- $1.05B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Biotechnology.
52-Week Trading Range
Over the past year, SRPT stock traded between $10.42 and $25.32—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 48.35% annualized volatility and β=1.63, the stock exhibits high sensitivity to market moves—making SRPT suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
uniQure Trends to Watch as Gene Therapy Bets Shift Beyond Hemgenix
QURE is sharpening its gene therapy focus through faster regulatory pathways, a streamlined business model and CNS pipeline expansion, with AMT-130 at the center.
Following FDA sNDA Acceptance Is Sarepta Therapeutics (SRPT) Still Undervalued?
FDA sNDA Acceptance Puts Sarepta Therapeutics Stock in Focus Sarepta Therapeutics (SRPT) recently reported that the FDA accepted supplemental New Drug Applications for AMONDYS 45 and VYONDYS 53, seeking conversion from accelerated to traditional approvals in Duchenne muscular dystrophy. This regulatory step, backed by Phase 3 ESSENCE data and real world evidence on efficacy trends and safety, gives investors a new reference point for evaluating Sarepta Therapeutics stock and its Duchenne...
The Bull Case For Sarepta Therapeutics (SRPT) Could Change Following FDA sNDA Acceptance On DMD Therapies
In June 2026, Sarepta Therapeutics announced that the FDA accepted supplemental New Drug Applications to convert accelerated approvals for its Duchenne muscular dystrophy exon-skipping therapies AMONDYS 45 and VYONDYS 53 to traditional approvals, with a PDUFA action date set for February 28, 2027. This move, backed by the ESSENCE confirmatory study and extensive real-world evidence across more than 1,800 treated patients, could be important for reinforcing the long-term regulatory footing of...
What It Means To Hold Moderna Stock In A Crash
The company's pipeline is more advanced than ever, but its history shows a pattern of deep, prolonged drops when the market turns.
2 Beaten-Down Stocks That Still Aren't Worth Buying
Your hard-earned money would be better spent elsewhere.
Ionis Pharmaceuticals Drops Another 9% as Bad News Piles Up
A Phase 3 trial failure has erased a year of gains for Ionis Pharmaceuticals in just days, and the ripple effects are rattling rivals across the RNA and rare-disease biotech space with more catalysts still ahead.
Moderna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech Rout
Moderna, ImmunityBio, and Sarepta are all cratering today despite bullish recent news and no negative catalysts in sight, leaving investors scrambling to understand whether the biotech sector's monster 2026 run has finally hit a wall.
Beyond The Breakout Drug: Is BridgeBio Pharma Stock A Buy On Its Next Act?
With its lead drug driving rapid growth and three more on deck, the biotech is betting it can outrun future competition and a history of volatility.
The Long Climb Back For Ionis Stock
A look at the company's history of deep drawdowns shows the real risk shareholders are carrying today.
Tractor Supply downgrade, Five Below upgraded: Wall Street's top analyst calls
Tractor Supply downgrade, Five Below upgraded: Wall Street's top analyst calls
Frequently Asked Questions
Common investor questions about Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc. (SRPT) is currently trading at $17.22. The RSI (14-day) is at 39.9, indicating neutral territory. Wall Street analysts have a consensus "hold" recommendation. The mean analyst price target of $22.00 implies 27.8% upside from current levels. Volatility is high at 48.4% annualized, meaning significant price swings are common. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Sarepta Therapeutics, Inc. (SRPT): The trailing P/E ratio is 49.20, which is above the market average, indicating investors are pricing in higher growth expectations. The forward P/E is 6.67, lower than the trailing P/E, suggesting analysts expect earnings improvement. Price-to-Book is 1.21. Price-to-Sales is 0.83. Valuation should be compared to Biotechnology industry peers for context, as different sectors trade at different multiples.
Based on 23 analysts covering SRPT, the consensus price target is $22.00. This represents a 27.8% upside from the current price of $17.22. The range spans from a low target of $5.00 to a high target of $38.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "hold". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Sarepta Therapeutics, Inc. (SRPT) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Sarepta Therapeutics, Inc. (SRPT) investors include: 1. High volatility (48.4% annualized)—the stock can experience significant daily price swings. 2. Declining revenue (-1.9% YoY), indicating potential business headwinds. 3. Elevated short interest (28.6% of float) suggests significant bearish sentiment. 4. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 5. Biotechnology sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Sarepta Therapeutics, Inc.'s (SRPT) current debt and financial health profile: Total debt stands at $1.05B. The debt-to-equity ratio is 69.57, which is moderate and generally manageable for most companies. The current ratio is 4.63, indicating strong short-term liquidity. The quick ratio is 2.41. The company holds $653.19M in cash and equivalents. Free cash flow is positive at $204.78M, providing a cushion for debt servicing and shareholder returns.